CanSino Biologics Inc
SSE:688185
CanSino Biologics Inc
Cash from Operating Activities
CanSino Biologics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CanSino Biologics Inc
SSE:688185
|
Cash from Operating Activities
-¥908.2m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Operating Activities
¥4.7B
|
CAGR 3-Years
22%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cash from Operating Activities
¥1.1B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
17%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Operating Activities
¥7.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Operating Activities
¥4.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Cash from Operating Activities
-¥705.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CanSino Biologics Inc
Glance View
CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
See Also
What is CanSino Biologics Inc's Cash from Operating Activities?
Cash from Operating Activities
-908.2m
CNY
Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Cash from Operating Activities amounts to -908.2m CNY.
What is CanSino Biologics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-49%
Over the last year, the Cash from Operating Activities growth was 51%. The average annual Cash from Operating Activities growth rates for CanSino Biologics Inc have been -25% over the past three years , -49% over the past five years .
You don't have any saved screeners yet